References
- Aungst B. J., Myers M. J., Shefter E., Shami E. G. Prodrugs for improved oral nalbuphine bioavailability: inter-species differences in the disposition of nalbuphine and its acetylsalicylate and anthranilate esters. Int. J. Pharm. 1987; 38: 199–209
- Hussain M. A., Koval C. A., Myers M. J., Shami E. G., Shefter E. Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach. J. Pharm. Sci. 1987; 76(5)356–358
- Hussain M. A., Shefter E. Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. Pharm. Res. 1988; 5(2)113–115
- Hussain M. A., Aungst B. J., Koval C. A., Shefter E. Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs. Pharm. Res. 1988; 5(9)615–618
- Hussain M. A., Aungst B., Shefter E. Prodrug for improved oral β-estradiol bioavailability. Pharm. Res. 1988; 5(1)44–47
- Jonsson T., Christensen C. B., Jordening H., Frolund C. The bioavailability of rectally administered morphine. Pharmacol. Toxicol. 1988; 62: 203–205
- Aungst B. J., Lam G., Shefter E. Oral and rectal nalbuphine bioavailability: first-pass metabolism in rats and dogs. Biopharm. Drug Dispos. 1985; 6: 413–421
- Nishihata T., Rytting J. H., Higuchi T. Effect of salicylate on rectal absorption of theophylline. J. Pharm. Sci. 1981; 70(1)71–75
- Paul D., Standifer K. M., Inturrisi C. E., Pasternak G. W. Pharmacological characterization of mor-phine-6β-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther. 1989; 251: 477–483
- Portenoy R. K., Foley K. M., Stulman J. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991; 47(1)13–19
- D'Honner G., Gillton A., Sandouk P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine: The influence of renal failure. Anesthesiology 1994; 81: 87–93
- Olsson O. A. T., Svensson L.-A. New lipophilic terbutaline ester prodrugs with long effect duration. Pharm. Res. 1984; 1: 19–23
- Stinchcomb A. L., Dua R., Paliwal A., Woodard R. W., Flynn G. L. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm. Res. 1995; 12: 1526–1529
- Health and Public Policy Committee. American College of Physicians: Drug therapy for severe, chronic pain in terminal illness. Recent Results Cancer Res. 1986; 108: 9–17